Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2001

View Archived Issues

Cypress Bioscience launches genomic program for fibromyalgia research

Amarillo Biosciences reports additional analysis of phase II data in FMS trial

Combination abciximab/reteplase therapy has benefits in MI

Hybrigenics and OGS establish proteomics collaboration

Dusa cleared to begin three phase I/II trials with Levulan for new indications

Synthetic peptide inhibits HIV-1 infection in vitro by activating FPRL1

GSK drops late-stage compound from pipeline

Two compounds enter preclinical development at Serono

Aminoguanidine and aspirin compared for their long-term effects on diabetic retinopathy

S. pneumoniae DNA vaccine encoding PPS4 peptide mimetic induces specific immune response in mice

Binding characteristics and effects on steroid synthesis of two new PBR ligands

EpiGenesis obtains license to Genta antisense patents

Phase I/II clinical trials of StreptAvax commence

Enzon begins phase II trial of Prothecan

Promising results reported from Multikine study in HPV-induced cervical dysplasia

Questcor's Emitasol receives approval in the Czech Republic and Poland

OSI-774 to be tested in combination therapy for NSCLC

Titan and Novartis to conduct further trials of iloperidone prior to submission

First market introduction announced for Zelmac

Recent Japanese patent covers new PPARgamma response element activators

Potential antidiabetic agents presented by Ferring

Antitumor bryostatin analogues synthesized at Leland Stanford

Preparation, telomerase-inhibitory and antitumor activity of new series from Aventis

Potent HIV protease inhibition seen in Abbott valinamide derivatives

Selective lck tyrosine kinase inhibitors and use in T-cell-mediated diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...